STIC-ILL

NO

From: Canella, Karen
Sent: Wednesday, January 21, 2004 8:06 PM
To: STIC-ILL
Subject: ill order PCT/US03/23845

47967

Art Unit 1642 Location Remsen 3A29 (office, I don't know my mail box address yet)

Telephone Number 272-0828

Application Number PCT/US03/23845

1. Cancer Biotherapy & Radiopharmaceuticals, 2000, 15(1):71-79

2. Cancer Research, 2002, 62(15):4263-4272

3. Women's Oncology Review, 2002, 2(4):411-412

4. CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2002:951264 CAPLUS
DOCUMENT NUMBER: 139:272943
TITLE: Direct electrophilic radiofluorination of a cyclic RGD peptide for in vivo .alpha.v.beta.3 integrin related tumor imaging
AUTHOR(S): Ogawa, Mikako; Hatano, Kentaro; Oishi, Shinya; Kawasumi, Yasuhiro; Fujii, Nobutaka; Kawaguchi, Michiya; Doi, Ryuichiro; Imamura, Masayuki; Yamamoto, Mikio; Ajito, Keiichi; Mukai, Takahiro; Saji, Hideo; Ito, Kengo
CORPORATE SOURCE: Department of Biofunctional Research, National Institute for Longevity Sciences, Gengo, Morioka-cho, Obu, 474-8522, Japan
SOURCE: Nuclear Medicine and Biology (2002), Volume Date 2003, 30(1), 1-9
CODEN: NMBIEO; ISSN: 0969-8051
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

D022012R

5. CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:894626 CAPLUS
DOCUMENT NUMBER: 135:89216
TITLE: Recent progress in the field of .alpha.v-integrin antagonists
AUTHOR(S): Kessler, Horst; Kantlehner, Martin; Gibson, Christoph; Haubner, Roland; Finsinger, Dirk; Dechantsreiter, Michael; Planker, Eckart; Wermuth, Jochen; Schmitt, Jorg S.; Meyer, Jorg; Schaffner, Patricia; Holzemann, Gunter; Wiesner, Matthias; Goodman, Simon L.; Hahn, Diane; Jonczyk, Alfred; Wester, Hans J.; Schwaiger, Markus
CORPORATE SOURCE: Institut fur Organische Chemie und Biochemie, Technische Universitat Munchen, Garching, 85747, Germany
SOURCE: Peptides for the New Millennium, Proceedings of the American Peptide Symposium, 16th, Minneapolis, MN, United States, June 26-July 1, 1999 (2000), Meeting Date 1999, 235-237. Editor(s): Fields, Gregg B.; Tam, James P.; Barany, George. Kluwer Academic Publishers: Dordrecht, Neth.
CODEN: 69ATHX
DOCUMENT TYPE: Conference
LANGUAGE: English
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS

BEST AVAILABLE COPY

Reprinted with permission by the Publisher. This material is protected by copyright and cannot be further reproduced or stored electronically without publisher permission and payment of a royalty fee for each copy made. All rights reserved.

Recent progress in the field of α_v-integrin antagonists

Horst Kessler,[1] Martin Kantlehner,[1] Christoph Gibson,[1] Roland Haubner,[1] Dirk Finsinger,[1] Michael Dechantsreiter,[1] Eckart Planker,[1] Jochen Wermuth,[1] Jörg S. Schmitt,[1] Jörg Meyer,[2] Patricia Schaffner,[2] Günter Hölzemann,[3] Matthias Wiesner,[3] Simon L. Goodman,[3] Diane Hahn,[3] Alfred Jonczyk,[3] Hans J. Wester,[4] and Markus Schwaiger[4]

[1]Institut für Organische Chemie und Biochemie, Technische Universität München, 85747 Garching, Germany; [2]Merck Biomaterial GmbH, Forschung, 64271 Darmstadt, Germany; [3]Merck KGaA, Präklinische Forschung, 64271 Darmstadt, Germany; and [4]Nuklearmedizinische Klinik und Poliklinik Rechts der Isar, Technische Universität München, 81675 München, Germany.

Introduction

Integrins - a class of heterodimeric, transmembrane glycoprotein receptors - play an important role in many physiological processes. The development of highly active and selective integrin antagonists is a promising approach for the treatment of various diseases. Cyclization and "spatial screening" yielded cyclo(RGDfV) [1,2] as highly active and selective $\alpha_v\beta_3$-integrin antagonist. Extensive peptidomimetic studies finally culminated in cyclo[RGDf-N(Mc)V] [3,4] which binds in the subnanomolar range and is selected for clinical phase I/II as as antiangiogenetic tumor drug (EMD 121974). Their NMR derived structures are shown in Fig. 1.



Fig. 1. NMR-derived solution structure of cyclo(RGDfV) and its N-methylated analog cyclo[RGDf-N(Me)V]. The N(Me) group imparts steric regulation via the peptide backbone resulting in a widened arrangement of the pharmacophoric RGD sequence. The structures show one of the side-chain conformations which interconvert fast in solution.

We report here about improving the activity, selectivity and bioavailability of these antagonists and the development of non-peptidic analogues via combinatorial techniques. Furthermore we functionalize our antagonists for special applications, e. g. surface coating or radionuclide medicine.

BEST AVAILABLE COPY

Results and Discussion

We found that X in cyclo(RGDfX) can be replaced by other amino acids without a remarkable change in activity and selectivity [5,6]. Replacement by Lys or Glu introduce useful functionalities for any derivatizations of the cyclopeptides.

For application in radionuclid diagnostic we synthesized the radiolabeled peptide with ^{125}I-D-Tyr instead of D-Phe: cyclo[RGD(^{125}I)yV]. After modifying the peptide by conjugation of a sugar amino acid (SAA) to the Lys side chain (X = K) the biodistribution and tumor accumulation of the glycosylated peptide cyclo(RGD(^{125}I)y[SAA]K) exhibited drastically improved biokinetics [7] compared with the non-glycosylated compound.

For biofunctionalization of inert surfaces we have coupled our highly active and $\alpha_v\beta_3$- and $\alpha_v\beta_5$-selective peptide cyclo(RGDfK) over the lysine side-chain to various linker-molecules containing acrylic acid as anchor functionality [8]. These peptides can be covalently linked to polymethylmethacrylate-(PMMA)-surfaces (Fig. 1). In contrast to untreated surfaces the coated surfaces bind murine osteoblasts as well as human osteoblasts very effectively *in vitro* if a critical minimum distance of 3.5 nm between surface and the constrained RGD-sequence is ensured (Fig. 2).



Fig. 2: Schematic function of RGD-coated surfaces.

Promising cell adhesion rates and strong cell attachments were observed, and surface bound cells started to proliferate. These findings may be helpful for the development of a new generation of bone implants as the peptides can provide a strong mechanical contact between implant surface and the surrounding healthy and new forming tissue.

Substitution within the RGD sequence in the lead peptide cyclo(RGDfV) mostly resulted in a loss of activity and selectivity. However, a remarkable difference was found with azaGly instead of Gly. This cyclic peptide exhibited full activity and according to NMR and DG studies showed a twisted NN bond [9,10]. This observation stimulated us to search for linear azaGly analogues and we found that we can modulate activity and selectivity in linear diacylhydrazines as well [11]. We found suitable reaction conditions to prepare activated Fmoc-protected azaglycine, azasarcosine and azaalanine in high yields, by treatment of the corresponding Fmoc-hydrazines with a commercially available solution of phosgene in toluene. To check the feasibility of preparing azapeptides and azapeptoids on a solid support, we carried out a systematic study of the coupling conditions and targeted the preparation of some RGD-mimetics, all of which contain azabuilding blocks instead of glycine.

BEST AVAILABLE COPY



The synthesized aza-RGD-mimetics exhibit varying activity and selectivity on the integrin receptors $\alpha_v\beta_3$ or $\alpha_{IIb}\beta_3$ depending on the substitution pattern of the azabuilding block. The results offer a potential application of azapeptides and azapeptoides as selectivity and activity inducing templates in pseudo biooligomers. We want to emphasize that our strategy afforded completely deprotected Fmoc-aminoethyl-photolinker [12] TentaGel-bound RGD-mimetics, which meet all requirements of the one-bead-one-compound concept [13] and allowed biological on-bead screening and subsequent chemical characterization via MS^n, due to orthogonal anchoring. For that purpose we have developed an on-bead assay for biological evaluation of aza-RGD-libraries.

Acknowledgments

We thank M. Wolff, M. Kranawetter and B. Cordes for technical assistance. Supported by the Sander-Stiftung (Grant No. 96.017.1), the Fonds der Chemischen Industrie and the Deutsche Forschungsgemeinschaft.

References

1. Aumailley, M., Gurrath, M., Müller, G., Calvete, J., Timpl, R., and Kessler, H., FEBS Lett. 291 (1991) 50.
2. Pfaff, M., Tangemann, K., Müller, B., Gurrath, M., Müller, G., Kessler, H., Timpl, R., and Engel, J., J. Biol. Chem. 269 (1994) 20233.
3. Dechantsreiter, M.A., Planker, E., Mathä, B., Lohof, E., Hölzemann, G., Jonczyk, A., Goodman, S.L., and Kessler, H., J. Med. Chem., in press.
4. Dechantsreiter, M.A., Thesis, München, 1998.
5. Haubner, R., Gratias, R., Diefenbach, B., Goodman, S.L., Jonczyk, A., and Kessler, H., J. Am. Chem. Soc. 118 (1996) 7461.
6. Haubner, R., Finsinger, D., and Kessler, H., Angew. Chem. Int. Ed. 36 (1997) 1374.
7. Haubner, R., Wester, H.J., Senekowitsch-Schmidtke, R., Diefenbach, B., Kessler, H., Stöcklin, G., and Schwaiger, M., J. Lab. Compd. Radiopharm. 40 (1997) 383.
8. Kantlehner, M., Finsinger, D., Meyer, J., Schaffner, P., Jonczyk, A., Diefenbach, B., Nies, B., and Kessler, H., Angew. Chem. Int. Ed. 38 (1999) 560.
9. Wermuth, J., Thesis, München, 1996.
10. Schmitt, J.S., Thesis, München, 1998.
11. Gibson, C., Goodman, S.L., Hahn, D., Hölzemann, G., and Kessler, H., J. Org. Chem., submitted.
12. Holmes, C.P., and Jones, D.G., J. Org. Chem. 60 (1995) 2318.
13. Lam, K.S., Salmon, S.E., Hersh, E.M., Hruby, V.J., Kazmierski, W.M., and Knapp, R.J. Nature 354 (1991) 82.
14. Lam, K.S., Lebl, M., and Krchnák, V., Chem. Rev. 97 (1997) 411.

BEST AVAILABLE COPY